Literature DB >> 8092846

Tetracycline resistance determinants in Mycobacterium and Streptomyces species.

Y Pang1, B A Brown, V A Steingrube, R J Wallace, M C Roberts.   

Abstract

Two of seven tetracycline-resistant (Tcr) Mycobacterium fortuitum group isolates and six Tcr clinical Streptomyces isolates carried gram-positive Tcr determinants (Tet K and Tet L) and Streptomyces resistance determinants (Otr A, Otr B, and Otr C). This represents the first documentation of the acquisition by mycobacteria of determinants coding for antibiotic resistance and suggests the potential for the spread of antibiotic resistance determinants within mycobacterial species.

Entities:  

Mesh:

Year:  1994        PMID: 8092846      PMCID: PMC188220          DOI: 10.1128/AAC.38.6.1408

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Conjugative transposons and the dissemination of antibiotic resistance in streptococci.

Authors:  D B Clewell; C Gawron-Burke
Journal:  Annu Rev Microbiol       Date:  1986       Impact factor: 15.500

2.  Molecular cloning of resistance genes and architecture of a linked gene cluster involved in biosynthesis of oxytetracycline by Streptomyces rimosus.

Authors:  M J Butler; E J Friend; I S Hunter; F S Kaczmarek; D A Sugden; M Warren
Journal:  Mol Gen Genet       Date:  1989-01

3.  Patterns and distribution of aminoglycoside-acetylating enzymes in rapidly growing mycobacteria.

Authors:  T Udou; Y Mizuguchi; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1987-08

4.  Presence of aminoglycoside acetyltransferase and plasmids in Mycobacterium fortuitum. Lack of correlation with intrinsic aminoglycoside resistance.

Authors:  S I Hull; R J Wallace; D G Bobey; K E Price; R A Goodhines; J M Swenson; V A Silcox
Journal:  Am Rev Respir Dis       Date:  1984-04

5.  Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  J R Dalovisio; G A Pankey; R J Wallace; D B Jones
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

6.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.

Authors:  J M Swenson; C Thornsberry; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

7.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

8.  Genetic basis of tetracycline resistance in urogenital bacteria.

Authors:  M C Roberts; S L Hillier
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 9.  Spectrum of disease due to rapidly growing mycobacteria.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good; J A Tschen; M S Stone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Human disease due to Mycobacterium smegmatis.

Authors:  R J Wallace; D R Nash; M Tsukamura; Z M Blacklock; V A Silcox
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

View more
  28 in total

Review 1.  Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.

Authors:  M C Roberts; J Sutcliffe; P Courvalin; L B Jensen; J Rood; H Seppala
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 2.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Nomenclature for new tetracycline resistance determinants.

Authors:  S B Levy; L M McMurry; T M Barbosa; V Burdett; P Courvalin; W Hillen; M C Roberts; J I Rood; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 4.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 5.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

6.  PCR detection of oxytetracycline resistance genes otr(A) and otr(B) in tetracycline-resistant streptomycete isolates from diverse habitats.

Authors:  Theodora L Nikolakopoulou; Sharon Egan; Leo S van Overbeek; Gilliane Guillaume; Holger Heuer; Elizabeth M H Wellington; Jan Dick van Elsas; Jean-Marc Collard; Kornelia Smalla; Amalia D Karagouni
Journal:  Curr Microbiol       Date:  2005-08-17       Impact factor: 2.188

Review 7.  The tetracycline resistome.

Authors:  Maulik Thaker; Peter Spanogiannopoulos; Gerard D Wright
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

8.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Antibacterial activity of and resistance to small molecule inhibitors of the ClpP peptidase.

Authors:  Corey L Compton; Karl R Schmitz; Robert T Sauer; Jason K Sello
Journal:  ACS Chem Biol       Date:  2013-10-04       Impact factor: 5.100

10.  Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.

Authors:  B A Brown; R J Wallace; G Onyi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.